ClinicalTrials.Veeva

Find clinical trials for Melanoma in Austin, TX

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Austin, TX, USA:

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

Phase 3

Aura Biosciences
Aura Biosciences

Austin, Texas, United States of America and 31 other locations

Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the f...

Active, not recruiting
Locally Advanced Unresectable or Metastatic Melanoma
Drug: Selinexor
Drug: Pembrolizumab

Phase 2

Karyopharm Therapeutics
Karyopharm Therapeutics

Austin, Texas, United States and 12 other locations

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Austin, Texas, United States and 171 other locations

and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...

Active, not recruiting
Melanoma
Biological: Nivolumab
Other: Placebo

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Austin, Texas, United States and 128 other locations

Locations recently updated

is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better ...

Enrolling
Melanoma
Biological: Pembrolizumab
Biological: V940

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Austin, Texas, United States and 125 other locations

This is an open-label, multicenter, first-in-human dose-escalation and expansion Phase 1-2 study designed to determine the safety, tolerability, phar...

Enrolling
Melanoma
Metastatic Cancer
Drug: Cemiplimab
Drug: OR2805

Phase 1, Phase 2

OncoResponse

Austin, Texas, United States and 2 other locations

The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in particip...

Active, not recruiting
Melanoma
Cancer
Biological: Ipilimumab
Other: Placebo

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Austin, Texas, United States and 74 other locations

The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors an...

Active, not recruiting
Melanoma
Solid Tumor
Drug: Niraparib

Phase 2

Tempus AI

Austin, Texas, United States and 79 other locations

This is a Phase 1/2, multicenter, open label, first in human (FIH) study of DCC-3116 as monotherapy, and in combination with trametinib, binimetinib,...

Enrolling
Melanoma
Advanced Solid Tumor
Drug: DCC-3116
Drug: Trametinib

Phase 1, Phase 2

Deciphera
Deciphera

Austin, Texas, United States and 7 other locations

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary...

Enrolling
Metastatic Solid Tumor
Drug: PLN-101095
Drug: Pembrolizumab

Phase 1

Pliant Therapeutics

Austin, Texas, United States and 3 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems